The Trans-Atlantic Trade and Investment Partnership (TTIP) will, when concluded, have far-reaching consequences for a number of economic sectors, including sectors such as pharmaceuticals, medical devices and cosmetics. Some hail the coming of TTIP as a unique opportunity to harmonize and streamline procedures, eliminate duplicate requirements and cut down a lot of red tape and unnecessary costs, resulting in a strengthening of the transatlantic health sector and, ultimately, improving public health. Others, however, are more critical, fearing that the introduction of TTIP could lead to a race to the bottom in terms of health standards. There is also a lot of uncertainty: what could be included in the agreement and what the implications could be for different sectors and thus for people’s health and the health sector in general? What are the biggest differences when it comes to regulating and ensuring good public health and consumer protection in the EU and the US and how could TTIP improve cooperation? How far can regulatory convergence go? These are the questions the all-stakeholder panel of this dialogue tried to address.